Global Acute Myeloid Leukemia Market By Type (Chemotherapy, Radiation Therapy, Stem Cell Transplant, Targeted Therapy, and Others), By Application (Hospital, Retails Drug Stores, Ambulatory Care Centers, Oncology Centers, and Clinics), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

Published date: Jul 2022
Report ID: 47836
Number of Pages: 317
Format:

- 1. Acute Myeloid Leukemia Market Introduction
  - 1.1. Definition
  - 1.2. Taxonomy
  - 1.3. Research Scope
- 2. Executive Summary
  - 2.1. Key Findings by Major Segments
  - 2.2. Top strategies by Major Players
- 3. Global Acute Myeloid Leukemia Market Overview
  - 3.1. Acute Myeloid Leukemia Market Dynamics
    3.1.1. Drivers
    3.1.2. Opportunities
    3.1.3. Restraints
    3.1.4. Challenges
  - 3.2. PESTLE Analysis
  - 3.3. Opportunity Map Analysis
  - 3.4. PORTER'S Five Forces Analysis
  - 3.5. Market Competition Scenario Analysis
  - 3.6. Product Life Cycle Analysis
  - 3.7. Opportunity Orbits
  - 3.8. Production Analysis by Region/Company
  - 3.9. Industry chain Analysis
  - 3.10. Marketing Strategy
- 4. Global Acute Myeloid Leukemia Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
  - 4.1. Global Acute Myeloid Leukemia Market Analysis by Type: Introduction
  - 4.2. Market Size and Forecast by Region
  - 4.3. Chemotherapy
  - 4.4. Radiation Therapy
  - 4.5. Stem Cell Transplant
  - 4.6. Targeted Therapy
  - 4.7. Others
- 5. Global Acute Myeloid Leukemia Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
  - 5.1. Global Acute Myeloid Leukemia Market Analysis by Application: Introduction
  - 5.2. Market Size and Forecast by Region
  - 5.3. Hospital
  - 5.4. Retails Drug Stores
  - 5.5. Ambulatory Care Centers
  - 5.6. Oncology Centers
  - 5.7. Clinics
- 6. Global Acute Myeloid Leukemia Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
  - 6.1. North America
    6.1.1. North America Acute Myeloid Leukemia Market: Regional Trend Analysis
    6.1.1.1. US
    6.1.1.2. Canada
    6.1.1.3. Mexico
  - 6.2.1. Europe
    6.2.1. Europe Acute Myeloid Leukemia Market: Regional Trend Analysis
    6.2.1.1. Germany
    6.2.1.2. France
    6.2.1.3. UK
    6.2.1.4. Russia
    6.2.1.5. Italy
    6.2.1.6. Spain
    6.2.1.7. Rest of Europe
  - 6.3. Asia-Pacific
    6.3.1. Asia-Pacific Acute Myeloid Leukemia Market: Regional Trend Analysis
    6.3.1.1. China
    6.3.1.2. Japan
    6.3.1.3. Korea
    6.3.1.4. India
    6.3.1.5. Rest of Asia-Pacific
  - 6.4. Latin America
    6.4.1. Latin America Acute Myeloid Leukemia Market: Regional Trend Analysis
    6.4.1.1. Brazil
    6.4.1.2. Argentina
    6.4.1.3. Rest of Latin America
  - 6.5. Middle East and Africa
    6.5.1. Middle East and Africa Acute Myeloid Leukemia Market: Regional Trend Analysis
    6.5.1.1. GCC
    6.5.1.2. South Africa
    6.5.1.3. Israel
    6.5.1.4. Rest of MEA
- 7. Global Acute Myeloid Leukemia Market Competitive Landscape, Market Share Analysis, and Company Profiles
  - 7.1. Market Share Analysis
  - 7.2. Company Profiles
  - 7.3. Celgene Corporation
    7.3.1. Company Overview
    7.3.2. Financial Highlights
    7.3.3. Product Portfolio
    7.3.4. SWOT Analysis
    7.3.5. Key Strategies and Developments
  - 7.4. Cephalon
    7.4.1. Company Overview
    7.4.2. Financial Highlights
    7.4.3. Product Portfolio
    7.4.4. SWOT Analysis
    7.4.5. Key Strategies and Developments
  - 7.5. Clavis Pharma
    7.5.1. Company Overview
    7.5.2. Financial Highlights
    7.5.3. Product Portfolio
    7.5.4. SWOT Analysis
    7.5.5. Key Strategies and Developments
  - 7.6. Eisai
    7.6.1. Company Overview
    7.6.2. Financial Highlights
    7.6.3. Product Portfolio
    7.6.4. SWOT Analysis
    7.6.5. Key Strategies and Developments
  - 7.7. Genzyme Corporation
    7.7.1. Company Overview
    7.7.2. Financial Highlights
    7.7.3. Product Portfolio
    7.7.4. SWOT Analysis
    7.7.5. Key Strategies and Developments
  - 7.8. Sunesis Pharmaceuticals
    7.8.1. Company Overview
    7.8.2. Financial Highlights
    7.8.3. Product Portfolio
    7.8.4. SWOT Analysis
    7.8.5. Key Strategies and Developments
  - 7.9. Abbvie
    7.9.1. Company Overview
    7.9.2. Financial Highlights
    7.9.3. Product Portfolio
    7.9.4. SWOT Analysis
    7.9.5. Key Strategies and Developments
  - 7.10. Astellas Pharma
    7.10.1. Company Overview
    7.10.2. Financial Highlights
    7.10.3. Product Portfolio
    7.10.4. SWOT Analysis
    7.10.5. Key Strategies and Developments
  - 7.11. CTI Biopharma Corp
    7.11.1. Company Overview
    7.11.2. Financial Highlights
    7.11.3. Product Portfolio
    7.11.4. SWOT Analysis
    7.11.5. Key Strategies and Developments
- 8. Assumptions and Acronyms
- 9. Research Methodology
- 10. Contact
- Celgene Corporation
- Cephalon
- Clavis Pharma
- Eisai
- Genzyme Corporation
- Sunesis Pharmaceuticals
- AbbVie Inc. Company Profile
- Astellas Pharma, Inc Company Profile
- CTI Biopharma Corp
Settings

Related Reports

Our Clients

✖

Request a Sample Report

We'll get back to you as quickly as possible

	Single User $5,999 $2,999 USD / per unit save 50%	Multi User $7,999 $3,499 USD / per unit save 55%	Corporate User $12,999 $4,499 USD / per unit save 65%
e-Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization	No	up to 10 hrs work	up to 30 hrs work
Accessibility	1 User	2-5 User	Unlimited
Analyst Support	up to 20 hrs	up to 40 hrs	up to 50 hrs
Benefit	Up to 20% off on next purchase	Up to 25% off on next purchase	Up to 30% off on next purchase
	Buy Now ($ 2,999)	Buy Now ($ 3,499)	Buy Now ($ 4,499)